Search

everythinglearnresearchcommunity

for

Search:↓

A user shared their 4-month progress using 5% topical minoxidil and 2 months of oral dutasteride for hair loss, experiencing significant shedding but also new hair growth. They reported side effects like increased body hair and temporary low libido, and are considering adding topical finasteride to their regimen.

A user shared their positive hair regrowth progress after using 1 mg oral finasteride and 5% minoxidil foam twice daily for four months. They experienced initial shedding but no side effects, and plan to switch to a cheaper minoxidil foam brand.

The conversation is about a person's two-year hair regrowth progress using finasteride, minoxidil, ketoconazole, and microneedling. They are comparing their hair from April 21, 2022, to April 13, 2024.

The conversation discusses hair regrowth results after using finasteride, minoxidil, and dermarolling for four months. Users inquire about dosages and when results were first noticed.

The conversation is about hair regrowth progress after 4 weeks of using 1mg Finasteride, with the user experiencing initial shedding followed by the appearance of small dark hairs on the scalp. Specific treatment mentioned is 1mg Finasteride.

The user increased their steroid dosage and noticed hair shedding, so they adjusted their regimen by reducing steroid doses and adding oral dutasteride. They are also experimenting with combining RU-58841 and KX-826/pyrilutamide in minoxidil to address hair loss.

The conversation is about finding a reliable Chinese source for pyrilutamide or RU58841, ideally with a third-party Certificate of Analysis from Janoshik Analytical. The user is seeking recommendations for these hair loss treatments.

Pyrilutamide is believed to be more effective than RU58841 and 1 mg finasteride in treating hair loss, with no systemic hormonal effects and the potential to block more than 31% of scalp DHT. It may also antagonize scalp testosterone due to its action as an androgen receptor antagonist.

The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.

User creates 0.1% topical finasteride solution using Alfatradiol Avixis base. Seeks help to ensure alfatradiol base dissolves finasteride.

Combining microneedling with Low Level Laser Therapy (LLLT) for hair growth, with discussions on device legitimacy and effectiveness. Alternatives like PEMF and the use of oral and topical treatments such as dutasteride, minoxidil, and finasteride are also considered.

The conversation discusses using 0.5mg Dutasteride once a week for hair loss, with suggestions to increase frequency for better results. The user plans to reassess the need for a hair transplant in six months and is concerned about potential side effects like gynecomastia.

A user's progress pictures and four month finasteride update showing dramatic hair regrowth, as well as their experiences with other treatments like minoxidil. The conversation also includes advice on diet, testosterone levels, and the importance of avoiding baldness for attraction and confidence.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

A user is exploring VEGF gene therapy to enhance hair transplant results, considering measuring hair shaft diameter and growth rate. Suggestions include using phototrichograms and possibly adding PRP, though its effectiveness is uncertain.

Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.

PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.

Hair loss treatments, specifically about the effectiveness of RU58841 compared to Pyrilutamide. Molecular weights and side effects were discussed in terms of efficacy and cost-effectiveness.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

The conversation is about the effectiveness of the Laduora duo massage brush for hair regrowth using vibration and red light, and whether the vitamin gel pods make sense. Specific treatments like Minoxidil, finasteride, and RU58841 are not mentioned.

JXL082 is not the same as PP405, leading to a halt in sales and a plan to synthesize the real PP405. There is skepticism about the safety and effectiveness of JXL082 and PP405, with concerns about patent issues and the long-term impact on hair growth.

A new topical treatment, TH07, combining finasteride, latanoprost, and minoxidil, is entering phase III trials with promising early results. Some users express skepticism, noting the treatment uses existing products.

Women experienced severe reactions, including Topical Steroid Withdrawal (TSW), from using Winlevi (Clascoterone 1%) on their faces. Concerns were raised about the potential risks of higher concentrations, especially for hair loss treatment.

ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.

The user has been using 0.5mg finasteride daily for 4 years and is considering adding minoxidil, either oral or topical, to improve hairline density. They are also contemplating a hair transplant and have been using derma rolling and ketoconazole inconsistently.

A 34 year old female with androgenic alopecia who has tried treatments such as Spironolactone, Desogen, Minoxidil and Finasteride in order to address her hair loss. It also details the experiences of other women taking Spironolactone for Female Pattern Hair Loss (FPHL).

The conversation discusses hair regrowth progress from Norwood scale 4 to 2.5 over a year using daily 8.5-9% RU58841, topical Dutasteride 0.1%, RU58841 5% 1.5 times a week, and daily caffeine redensyl scalp treatment.

The user has been using 1.5mg finasteride daily for four months and added minoxidil with a dermaroller for one month but stopped due to eye floaters. There is some improvement in hair regrowth, and suggestions include continuing treatment, using ketoconazole shampoo, and considering other supplements like vitamin D, saw palmetto, and biotin.

The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.

Hair loss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicle regeneration, but no updates on SCUBE3.